Based on the key indicators related to Apellis Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Apellis Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, Apellis Pharmaceuticals' Inventory is comparatively stable compared to the past year. Other Current Assets is likely to gain to about 73.9 M in 2025, whereas Property Plant And Equipment Net is likely to drop slightly above 17.7 M in 2025. Key indicators impacting Apellis Pharmaceuticals' financial strength include:
Investors should never underestimate Apellis Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Apellis Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Apellis Pharmaceuticals.
Net Income
(451.98 Million)
Apellis
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Net Borrowings
Total Cashflows From Investing Activities
Change To Account Receivables
Change To Operating Activities
Change To Netincome
Change To Liabilities
Investments
Change To Inventory
Issuance Of Capital Stock
Other Cashflows From Investing Activities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Common Stock
Net Tangible Assets
Non Currrent Assets Other
Other Assets
Property Plant Equipment
Capital Surpluse
Non Current Liabilities Total
Short Long Term Debt Total
Other Liab
Long Term Debt
Long Term Debt Total
Net Invested Capital
Net Working Capital
Short Term Debt
Capital Stock
Capital Lease Obligations
Short Term Investments
Non Current Liabilities Other
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Total Revenue
Gross Profit
Net Income From Continuing Ops
Cost Of Revenue
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Interest Income
Reconciled Depreciation
Tax Provision
Probability Of Bankruptcy
Understanding current and past Apellis Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Apellis Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Apellis Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Apellis Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Apellis Pharmaceuticals. Check Apellis Pharmaceuticals' Beneish M Score to see the likelihood of Apellis Pharmaceuticals' management manipulating its earnings.
Apellis Pharmaceuticals Stock Summary
Apellis Pharmaceuticals competes with Akero Therapeutics, Immunovant, Madrigal Pharmaceuticals, Day One, and Amylyx Pharmaceuticals. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Apellis Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Apellis Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Apellis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Apellis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Apellis Pharmaceuticals competition to find correlations between indicators driving Apellis Pharmaceuticals's intrinsic value. More Info.
Apellis Pharmaceuticals is rated below average in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, Apellis Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Apellis Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Apellis Pharmaceuticals Systematic Risk
Apellis Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Apellis Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Apellis Pharmaceuticals correlated with the market. If Beta is less than 0 Apellis Pharmaceuticals generally moves in the opposite direction as compared to the market. If Apellis Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Apellis Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Apellis Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Apellis Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Apellis Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Apellis Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Apellis Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.46
At this time, Apellis Pharmaceuticals' Price Earnings To Growth Ratio is comparatively stable compared to the past year.
Apellis Pharmaceuticals January 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Apellis Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Apellis Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Apellis Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Apellis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Apellis Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.